AI Market Mood: Stock Dashboard
SMMT
Fundamental
Company: Summit Therapeutics Inc
Sector: Healthcare
Industry: Biotechnology
Country: USA
Exchange: NASD
Index: -
P/E: -
EPS (ttm): -0.33
Insider Own: 84.99%
Shs Outstand: 741.61M
Perf Week: 9.43%
Market Cap: 21.29B
Forward P/E: -
EPS next Y: -0.52
Insider Trans: 0.00%
Shs Float: 111.44M
Perf Month: 34.79%
Enterprise Value: 20.94B
PEG: -
EPS next Q: -0.09
Inst Own: 13.21%
Short Float: 25.63%
Perf Quarter: -21.88%
Income: -240.75M
P/S: -
EPS this Y: -28.39%
Inst Trans: 7.34%
Short Ratio: 6.26
Perf Half Y: 16.31%
Sales: 0.00M
P/B: 61.75
EPS next Y Percentage: -30.83%
ROA: -85.89%
Short Interest: 28.56M
Perf YTD: 60.66%
Book/sh: 0.46
P/C: 58.88
EPS next 5Y: -21.52%
ROE: -123.93%
52W High: 36.91 -22.32%
Perf Year: 184.14%
Cash/sh: 0.49
P/FCF: -
EPS past 3/5Y: 31.56% -10.52%
ROIC: -69.33%
52W Low: 8.88 222.86%
Perf 3Y: 2350.43%
Dividend Est.: -
EV/EBITDA: -
Sales past 3/5Y: - -
Gross Margin: -
Volatility W: 5.07%
Volatility M: 6.95%
Perf 5Y: 670.70%
Dividend TTM: -
EV/Sales: -
EPS Y/Y TTM: -99.70%
Oper. Margin: -
ATR (14): 1.70
Perf 10Y: 166.20%
Dividend Ex-Date: -
Quick Ratio: 10.63
Sales Y/Y TTM: -100.00%
Profit Margin: -
RSI (14): 64.47
Recom: 1.31
Dividend Gr. 3/5Y: - -
Current Ratio: 10.63
EPS Q/Q: -37.64%
SMA20: 14.57%
Beta: -1.05
Target Price: 33.73
Payout: -
Debt/Eq: 0.02
Sales Q/Q: -
SMA50: 23.84%
Rel Volume: 0.39
Prev Close: 27.57
Employees: 159
LT Debt/Eq: 0.01
Earnings: May 01 AMC
SMA200: 35.26%
Avg Volume: 4.57M
Price: 28.67
IPO: Mar 05, 2015
Option/Short: Yes / Yes
EPS/Sales Surpr.: 3.23% -
Trades:
Volume: 1,788,759
Change: 3.99%
Technical:
Latest News:
Citigroup Initiates Coverage of Summit Therapeutics (SMMT) with Buy Recommendation very bullish
SMMT
Summary: Citigroup initiated coverage of Summit Therapeutics with a Buy recommendation, projecting a 53.67% upside potential. Various funds and institutions are increasing their positions, with a bullish sentiment indicated by the put/call ratio of 0.35.
Full article2024-05-08T17:42:16Z